Potential claims generally involve medications containing the active ingredient semaglutide or tirzepatide, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound
GLP-1 agonists Drug Class Insights The Drug Class Insights section will provide comprehensive information on Glucagon-like Peptide-1 (GLP-1) Agonists as a class
In Phase 3 TRIUMPH-1 (May 21, 2026), the 12 mg arm averaged 28.3% weight loss at 80 weeks, and a higher-BMI subgroup reached 30.3% at 104 weeks
Forbes Health
Semaglutide (Ozempic, Wegovy) has a half-life of approximately 7 days and takes about 5 weeks (five half-lives) for 97% clearance from the body after the final injection
o AstraZeneca PLC o Roche Holding AG o Zealand Pharma A/S o Hanmi Pharmaceutical Co., Ltd